Natural Human Interferon β Plus Ribavirin Combination Therapy in Japanese Patients Infected with Hepatitis C Virus and a High Viral Load

被引：10

作者：

Katamura, Yoshio ^{[1
]}

Suzuki, Fumitaka ^{[1
]}

Akuta, Norio ^{[1
]}

Sezaki, Hitomi ^{[1
]}

Yatsuji, Hiromi ^{[1
]}

Nomura, Norihiro ^{[1
]}

Kawamura, Yusuke ^{[1
]}

Hosaka, Tetsuya ^{[1
]}

Kobayashi, Masahiro ^{[1
]}

Suzuki, Yoshiyuki ^{[1
]}

Saito, Satoshi ^{[1
]}

Arase, Yasuji ^{[1
]}

Ikeda, Kenji ^{[1
]}

Kobayashi, Mariko ^{[2
]}

Kumada, Hiromitsu ^{[1
]}

机构：

[1] Toranomon Gen Hosp, Dept Hepatol, Tokyo, Japan

[2] Toranomon Gen Hosp, Res Inst Hepatol, Tokyo, Japan

来源：

INTERNAL MEDICINE | 2008年 / 47卷 / 21期

关键词：

hepatitis C virus; interferon beta; ribavirin; depression;

D O I：

10.2169/internalmedicine.47.1436

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Objective The aim of this pilot study was to determine the safety and efficacy of natural human interferon beta (nIFN beta) plus ribavirin (RBV) in patients with chronic hepatitis C who did not respond to pegylated interferon alpha (PEG-IFN), with special emphasis on the incidence of mental disorders or refusal for fear of adverse effects. Methods We studied 19 patients with HCV genotype 1b, 2a or 2b and a high viral load, including 8 patients with mental disorders. They were treated with nIFN beta-RBV. Eleven patients with HCV genotype 1b of these patients were treated with nIFN beta-RBV for 48 weeks (group A), and compared with 22 matched controls treated with PEG-IFN plus RBV for 48 weeks (group B). The other 8 patients with HCV genotype 2 were treated with nIFN beta-RBV for 24 weeks. Results Six of 8 patients with mental disorders and 9 of 11 patients without mental disorders completed nIFN beta-RBV therapy; 1 patient with mental disorder dropped out due to exacerbation of depression, and 3 patients suspended the therapy due to insufficient response. The sustained virological response (SVR) was 27% (3/11) in group A and 41% (9/22) in group B (p = 0.70). During treatment, platelet count increased in group A but not in group B. SVR was 88% (7/8) in patients of genotype 2 and high viral load treated with nIFN beta plus RBV. Conclusion nIFN beta-RBV therapy offers sufficient safety and efficacy for patients with mental disorders, and thus could represent an excellent second-line therapy for subpopulations that are not suitable for PEG-IFN-RBV.

引用

页码：1827 / 1834

页数：8

共 25 条

[1] INTERFERON-BETA TREATMENT OF HUMAN-DISEASE [J].